

US CLAIMS

1. Antigenic preparation directed against the PMWS syndrome, comprising porcine circovirus antigen and
5 porcine parvovirus antigen.

2. Preparation according to Claim 1, wherein it comprises type II porcine circovirus antigen.

3. Preparation according to Claim 1 or 2, wherein the porcine circovirus antigen and the porcine
10 parvovirus antigen comprise, independently of each other, an antigen chosen from the group consisting of an attenuated live whole antigen, an inactivated whole antigen, a subunit antigen, a recombinant live vector and a DNA vector.

15 4. Preparation according to claim 2, wherein the type II porcine circovirus antigen is an antigen of a circovirus selected from the group consisting of the preparations deposited at the ECACC, under the following references :

- 20 - accession No. V97100219
- accession No. V97100218
- accession No. V97100217
- accession No. V98011608
- accession No. V98011609

25 5. Preparation according to claim 1, wherein it comprises, in addition, an other valency which corresponds to another pig pathogen.

6. Preparation according to claim 5, wherein it comprises an other valency chosen among the group
30 consisting of : PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, E. coli, Atrophic Rhinitis, Pseudorabies, Hog cholera, Swine Influenza and combinations thereof.

7. Preparation according to claim 5, wherein it
35 comprises an other valency which is PRRS.

8. Vaccine against the PMWS syndrome, comprising an effective quantity of an antigenic preparation according to Claim 1, in a vehicle or excipient acceptable from the veterinary point of view.

09784062021601

9. Vaccine according to claim 6, wherein it comprises type II porcine circovirus antigen.

10. Vaccine according to claim 6, wherein it comprises an adjuvant acceptable from the veterinary point of view.

11. Vaccine according to claim 9, wherein the type II antigen is an antigen of a circovirus selected from the group consisting of the preparations deposited at the ECACC, under the following references :

- accession No. V97100219
- accession No. V97100218
- accession No. V97100217
- accession No. V98011608
- accession No. V98011609

12. Vaccine according to claim 9, wherein the vaccine comprises an attenuated live whole circovirus antigen, in a vehicle or diluent acceptable from the veterinary point of view.

13. Vaccine according to claim 12, wherein it comprises an adjuvant acceptable from the veterinary point of view.

14. Vaccine according to claim 12, wherein it comprises a freeze-drying stabilizer.

15. Vaccine according to claim 9, wherein the circovirus antigen is inactivated and the vaccine comprises, in addition, a vehicle or diluent acceptable from the veterinary point of view.

16. Vaccine according to claim 15, wherein it comprises an adjuvant acceptable from the veterinary point of view.

17. Vaccine according to claim 8, wherein it comprises antigens of several porcine circoviruses.

18. Vaccine according to claim 8, wherein it comprises, in addition, another valency which corresponds to another pig pathogen.

19. Vaccine according to claim 9, wherein it comprises, in addition, an another valency which corresponds to another pig pathogen.

007849620460

5

comprises another valency which is PRRS.

10

15

20

25

30

35.

viral vector is a virus selected from the group

consisting of Aujeszky's disease virus, vaccinia virus, avipox virus, canarypox virus and swine pox virus.

29. Vaccination kit containing, packaged separately, a vaccine against the porcine circovirus, and a vaccine against the porcine parvovirus.

30. Vaccination kit according to claim 29, wherein the circovirus is of type II.

31. Method of vaccination of porcines against PMWS syndrome, comprising the administration of a vaccine against the porcine circovirus and of a vaccine against the porcine parvovirus.

32. Method according to claim 31, wherein the vaccine are contained in the same formulations.

33. Method according to claim 31, wherein the circovirus is of type II.

34. Method according to claim 31, wherein the porcine circovirus antigen and the porcine parvovirus antigen comprise, independently of each other, an antigen chosen from the group consisting of an attenuated live whole antigen, an inactivated whole antigen, a subunit antigen, a recombinant live vector and a DNA vector.

35. Method according to claim 31, wherein the type II porcine circovirus antigen includes an antigen of a circovirus selected from the group consisting of the preparations deposited at the ECACC, under the following references :

- accession No. V97100219
- accession No. V97100218
- accession No. V97100217
- accession No. V98011608
- accession No. V98011609.

36. Method of vaccination of porcines, comprising the administration of a vaccine against the porcine circovirus, of a vaccine against the porcine parvovirus and of a vaccine against a pig pathogen chosen among the group consisting of : PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, E.

097496 021604

coli, Atrophic Rhinitis, Pseudorabies, Hog cholera, Swine Influenza and combinations thereof.

37. Method of vaccination of porcines, comprising the administration of a vaccine against the porcine circovirus, of a vaccine against the porcine parvovirus and of a vaccine against PRRS.
- 5

TOGETHER